Analyst Research Report Snapshot

Title:

UCB S.A.

Price:

$175.00

Provider:

MarketLine (a Datamonitor Company)

Date:

16 Feb 2015

Pages:

57

Type:

AcrobatPDF

Companies referenced:

UCB.BR

Available for Immediate Download
Summary:

UCB S.A. - Strategy and SWOT Report, is a source of comprehensive company data and information. The report covers the company’s structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360° view of the company. Features: - Detailed information on UCB S.A. required for business and competitor intelligence needs - A study of the major internal and external factors affecting UCB S.A. in the form of a SWOT analysis - An in-depth view of the business model of UCB S.A. including a breakdown and examination of key business segments - Intelligence on UCB S.A.’s mergers and acquisitions (M&A), strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors - News about UCB S.A., such as business expansion, restructuring, and contract wins - Large number of easy-to-grasp charts and graphs that present important data and key trends Highlights: UCB (or 'the company') is a global biopharmaceutical company focused on the discovery and development for people living with severe diseases of the immune system or of the central nervous system (CNS). It has operations in about 40 countries across Europe, North America and Asia Pacific. It is headquartered in Brussels, Belgium, and employed 8,732 people as of December 31, 2013. The company recorded revenues of E3,411 million (approximately $4,529.5 million) during the financial year ended December 2013 (FY2013), a decrease of 1.5% compared with FY2012. The operating profit of the company was E403 million (approximately $535.1 million) during FY2013, a decrease of 3.6% compared with FY2012. The net profit was E207 million (approximately $274.9 million) in FY2013, a decrease of 16.9% compared with FY2012. Reasons to Purchase: - Gain understanding of UCB S.A. and the factors that influence its strategies - Track strategic initiatives of the company and latest corporate news and actions - Assess UCB S.A. as a prospective partner, vendor or supplier - Support sales activities by understanding your customers' businesses better - Stay up to date on UCB S.A.’s business structure, strategy and prospects

Why buy analyst research?

  • Institutional quality research
  • Available for Immediate Download
  • Detailed company or industry insight
  • Print or save
  • 24 hour customer support
Return to previous page without adding this item to your cart.
Email Customer Support.

About Analyst Research

Analyst research reports are available for immediate download after purchase. You will have unlimited access to the report for 24 hours after purchase, to download, print or save it as many times as you wish. Analyst Research provided by Reuters does not constitute investment advice, and is not endorsed by Reuters Research. This information is protected by copyright and intellectual property laws. More information on Analyst Research.